A systematic review of the comparative safety of colloids.
OBJECTIVE
Safety differences exist among colloids widely used for fluid management in acutely ill patients, as judged according to the comparative incidence of adverse events.


METHODS
Colloid safety data for human subjects were sought, without language or time period restrictions, by means of computer searches of bibliographic and clinical trial databases, hand searches of medical journals and Index Medicus, inquiries with investigators and colloid suppliers, and examination of reference lists. Search terms included "colloids", "morbidity", and "mortality".


METHODS
Controlled trials, cohort studies, pharmacovigilance studies, and prior meta-analyses were independently selected by 2 unblinded investigators. Of 189 candidate studies, 113 were included, with safety data encompassing 1.54 x 10(6) patients and 1.09 x 10(8) colloid infusions.


METHODS
Two unblinded investigators independently extracted data. Study limitations and confounding factors were tabulated.


RESULTS
With albumin as the reference colloid, the incidence rate ratio for anaphylactoid reactions was 4.51 (95% confidence interval, 2.06-9.89) after hydroxyethyl starch administration, 2.32 (95% confidence interval, 1.21-4.45) after dextran, and 12.4 (95% confidence interval, 6.40-24.0) after gelatin. Pruritus occurrence was significantly increased by hydroxyethyl starch exposure (odds ratio, 1.78; 95% confidence interval, 1.23-2.58). Artificial colloid administration was consistently associated with coagulopathy and clinical bleeding, most frequently in cardiac surgery patients receiving hydroxyethyl starch. On the basis of large-scale pharmacovigilance study results, albumin infusion resulted in a low rate of both total adverse events (3.1 to 8.6 per 10(5) infusions) and serious adverse events (1.29 per 10(6) infusions).


CONCLUSIONS
Significant safety differences exist among colloids. Therefore, conclusions regarding the clinical usefulness of colloids as a fluid class should be formed with caution.
Barron
Michael E
ME
Department of Anesthesiology, University of Miami School of Medicine, Miami, FL, USA.
Wilkes
Mahlon M
MM
Navickis
Roberta J
RJ
D000418:Albumins / Q000008:administration & dosage / Q000627:therapeutic use; D003102:Colloids / Q000627:therapeutic use*; D003911:Dextrans / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005440:Fluid Therapy; D005780:Gelatin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage / Q000627:therapeutic use; D016017:Odds Ratio; D010952:Plasma Substitutes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011537:Pruritus / Q000139:chemically induced
D000418:Albumins; D003102:Colloids; D003911:Dextrans; D006895:Hydroxyethyl Starch Derivatives; D010952:Plasma Substitutes; D005780:Gelatin